DEAD box 1: a novel and independent prognostic marker for early recurrence in breast cancer - PubMed (original) (raw)
DEAD box 1: a novel and independent prognostic marker for early recurrence in breast cancer
Devon R Germain et al. Breast Cancer Res Treat. 2011 May.
Abstract
Breast cancer is a heterogeneous disease characterized by diverse molecular signatures and a variable response to therapy. Clinical management of breast cancer is guided by the expression of estrogen and progesterone receptors and HER2 amplification. New prognostic and predictive markers, as well as additional targets for therapy, are needed for more effective management of this disease. Gene expression microarrays were probed with RNAs from 176 primary breast cancer samples and tissue microarrays immunostained with anti-DDX1 antibody, an antibody to DEAD box protein DDX1, a putative RNA-RNA and RNA-DNA unwinding protein normally found in the nucleus. Half of the patient cohort had experienced early relapse despite standard adjuvant therapy, but were otherwise matched for estrogen receptor and HER2 status, stage and duration of follow-up. Here, we identify DDX1 RNA overexpression as an independent prognostic marker for early recurrence in primary breast cancer, with a hazard ratio of 4.31 based on logrank analysis of Kaplan-Meier curves. Elevated levels of DDX1 protein in the cytoplasm also independently correlate with early recurrence with a hazard ratio of 1.90. In conclusion, our data indicate a strong and independent association between poor prognosis and deregulation of the DEAD box protein DDX1. We propose that elevated levels of DDX1 RNA or the presence of DDX1 in the cytoplasm could serve as an effective prognostic biomarker for early recurrence in primary breast cancer.
Comment in
- Dead-box or black-box: is DDX1 a potential biomarker in breast cancer?
Balko JM, Arteaga CL. Balko JM, et al. Breast Cancer Res Treat. 2011 May;127(1):65-7. doi: 10.1007/s10549-010-1105-7. Epub 2010 Aug 8. Breast Cancer Res Treat. 2011. PMID: 20694745 No abstract available.
Similar articles
- DEAD box 1 (DDX1) expression predicts for local control and overall survival in early stage, node-negative breast cancer.
Taunk NK, Goyal S, Wu H, Moran MS, Chen S, Haffty BG. Taunk NK, et al. Cancer. 2012 Feb 15;118(4):888-98. doi: 10.1002/cncr.26352. Epub 2011 Jul 14. Cancer. 2012. PMID: 21761397 - Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, Ahr A. Rody A, et al. Zentralbl Gynakol. 2006 Apr;128(2):76-81. doi: 10.1055/s-2006-921508. Zentralbl Gynakol. 2006. PMID: 16673249 Clinical Trial. - Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
Nagai MA, Gerhard R, Fregnani JH, Nonogaki S, Rierger RB, Netto MM, Soares FA. Nagai MA, et al. Breast Cancer Res Treat. 2011 Feb;126(1):1-14. doi: 10.1007/s10549-010-0867-2. Epub 2010 Apr 6. Breast Cancer Res Treat. 2011. PMID: 20369286 - Gene expression profiles and prognostic markers for primary breast cancer.
Wang Y, Klijn J, Zhang Y, Atkins D, Foekens J. Wang Y, et al. Methods Mol Biol. 2007;377:131-8. doi: 10.1007/978-1-59745-390-5_7. Methods Mol Biol. 2007. PMID: 17634613 Review. - [Gene expression based multigene prognostic and predictive tests in breast cancer].
Pénzváltó Z, Mihály Z, Gyorffy B. Pénzváltó Z, et al. Magy Onkol. 2009 Dec;53(4):351-9. doi: 10.1556/MOnkol.53.2009.4.4. Magy Onkol. 2009. PMID: 20071307 Review. Hungarian.
Cited by
- Role and therapeutic potential of DEAD-box RNA helicase family in colorectal cancer.
Zheng B, Chen X, Ling Q, Cheng Q, Ye S. Zheng B, et al. Front Oncol. 2023 Oct 27;13:1278282. doi: 10.3389/fonc.2023.1278282. eCollection 2023. Front Oncol. 2023. PMID: 38023215 Free PMC article. Review. - A Hybrid Machine Learning Approach to Screen Optimal Predictors for the Classification of Primary Breast Tumors from Gene Expression Microarray Data.
Alromema N, Syed AH, Khan T. Alromema N, et al. Diagnostics (Basel). 2023 Feb 13;13(4):708. doi: 10.3390/diagnostics13040708. Diagnostics (Basel). 2023. PMID: 36832196 Free PMC article. - Synthetic lethal interactions of DEAD/H-box helicases as targets for cancer therapy.
Arna AB, Patel H, Singh RS, Vizeacoumar FS, Kusalik A, Freywald A, Vizeacoumar FJ, Wu Y. Arna AB, et al. Front Oncol. 2023 Jan 26;12:1087989. doi: 10.3389/fonc.2022.1087989. eCollection 2022. Front Oncol. 2023. PMID: 36761420 Free PMC article. Review. - DDX1 is a prognostic biomarker and correlates with immune infiltrations in hepatocellular carcinoma.
Yuan M, Xu J, Cao S, Sun S. Yuan M, et al. BMC Immunol. 2022 Nov 30;23(1):59. doi: 10.1186/s12865-022-00533-0. BMC Immunol. 2022. PMID: 36451087 Free PMC article. - Identification and Validation in a Novel Classification of Helicase Patterns for the Prediction of Tumor Proliferation and Prognosis.
Yin Y, Xu ZY, Liu YJ, Huang W, Zhang Q, Li JP, Zou X. Yin Y, et al. J Hepatocell Carcinoma. 2022 Aug 27;9:885-900. doi: 10.2147/JHC.S378175. eCollection 2022. J Hepatocell Carcinoma. 2022. PMID: 36061235 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous